July 31, 2026 · Form 4 insider transaction
Hyperscale Data, Inc. bought 7,500 shares of Alzamend Neuro, Inc. at $1000.00 per share, a transaction worth $7.50M. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Each share of Series D Convertible Preferred Stock has a stated value of $1,050.00 and is convertible into shares of Common Stock at a conversion price equal to the greater of (i) $0.2668 and (ii) 80% of the lowest closing bid price of the Common Stock during the five (5) trading days immediately prior to the date of conversion into conversion shares, but not greater than $2.00 per share (the "Conversion Price"). The Conversion Price is subject to adjustment in the event of issuances of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.; The Series D Convertible Preferred Stock has no expiration date.; As of August 4, 2026, the Conversion Price was $1.016 per share, so each share of Series D Convertible Preferred Stock is convertible into approximately 1,033.5 shares of Common Stock.; Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Capital Group, Inc. ("ACG"). ACG is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.